Pd22-12 a Phase-1 Trial of Real-Time Intraoperative Fluorescent Imaging of Nerve Structures Using Illuminare-1, a Novel Myelin Binding Fluorophore

You have accessJournal of UrologySurgical Technology 1 patient achieved fluorescence of 4 for 70 minutes. 3 patients achieved grade 4 fluorescence for 0, 66, and 87 minutes. One patient had a self-limited rash (Clavien 2), possibly attributable to the drug. CONCLUSIONS: The dose-escalation phase I study of Illuminare-1 has demonstrated promising results with minimal complications in the first 18 patients to receive the agent. We plan to identify a clinically useful and safe dose to inform further studies. Download PPT Source of Funding: Illuminare Biotechnologies © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e466 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Maria M. Pere More articles by this author Alex D. Doudt More articles by this author Trey D. Durdin More articles by this author Andrew W. Silagy More articles by this author Luke W. Dean More articles by this author Pedro Recabal More articles by this author Erica Levine More articles by this author Ouathek Ouerfelli More articles by this author Vanessa Thompson More articles by this author Alan Burke More articles by this author Melissa McCarter More articles by this author Christian Hernandez More articles by this author Andrew J. Vickers More articles by this author Peter T. Scardino More articles by this author Jonathan A. Coleman More articles by this author James A. Eastham More articles by this author Vincent P. Laudone More articles by this author Timothy F. Donahue More articles by this author Expand All Advertisement PDF downloadLoading ...